1887

Abstract

Hepatitis A virus (HAV) infections result in different courses of the disease, varying between normal, prolonged and relapsing. However, the reason for these heterogeneous clinical appearances is not understood. As HAV–anti-HAV IgA immunocomplexes (HAV–IgA) infect hepatocytes, IgA was postulated as a carrier supporting hepatotropic transport of HAV, and it was speculated that this carrier mechanism contributes to the various clinical outcomes. In this study, the IgA-carrier mechanism was investigated in a mouse model. We show that HAV–IgA immunocomplexes efficiently reached the liver not only in HAV-seronegative mice, but also, and this is in contrast to free-HAV particles, in immunized HAV-seropositive animals. This IgA-mediated transport of HAV to the liver in the presence of immunity depended on the stage of development of the immune response. We conclude that over a period of several weeks after infection, anti-HAV IgA is able to promote an enterohepatic cycling of HAV, resulting in continuous endogenous reinfections of the liver. Our experiments indicate that highly avid IgG antibodies, which are present at later times of the infection, can terminate the reinfections. However, the endogenous reinfections in the presence of a developing neutralizing immunity might contribute to prolonged as well as to relapsing courses of HAV infections. Furthermore, the results show that serum IgA may act as an infection protracting factor.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.038406-0
2012-04-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/93/4/754.html?itemId=/content/journal/jgv/10.1099/vir.0.038406-0&mimeType=html&fmt=ahah

References

  1. Brack K., Frings W., Dotzauer A., Vallbracht A. 1998; A cytopathogenic, apoptosis-inducing variant of hepatitis A virus. J Virol 72:3370–3376[PubMed]
    [Google Scholar]
  2. Brown T. A., Russell M. W., Mestecky J. 1984; Elimination of intestinally absorbed antigen into the bile by IgA. J Immunol 132:780–782[PubMed]
    [Google Scholar]
  3. Cromeans T., Sobsey M. D., Fields H. A. 1987; Development of a plaque assay for a cytopathic, rapidly replicating isolate of hepatitis A virus. J Med Virol 22:45–56 [View Article][PubMed]
    [Google Scholar]
  4. Dotzauer A., Gebhardt U., Bieback K., Göttke U., Kracke A., Mages J., Lemon S. M., Vallbracht A. 2000; Hepatitis A virus-specific immunoglobulin A mediates infection of hepatocytes with hepatitis A virus via the asialoglycoprotein receptor. J Virol 74:10950–10957 [View Article][PubMed]
    [Google Scholar]
  5. Dotzauer A., Brenner M., Gebhardt U., Vallbracht A. 2005; IgA-coated particles of hepatitis A virus are translocalized antivectorially from the apical to the basolateral site of polarized epithelial cells via the polymeric immunoglobulin receptor. J Gen Virol 86:2747–2751 [View Article][PubMed]
    [Google Scholar]
  6. Feigelstock D., Thompson P., Mattoo P., Zhang Y., Kaplan G. G. 1998; The human homolog of HAVcr-1 codes for a hepatitis A virus cellular receptor. J Virol 72:6621–6628[PubMed]
    [Google Scholar]
  7. Flehmig B., Zahn J., Vallbracht A. 1984; Levels of neutralizing and binding antibodies to hepatitis-A virus after onset of icterus: a comparison. J Infect Dis 150:461 [View Article][PubMed]
    [Google Scholar]
  8. Fleischer B., Fleischer S., Maier K., Wiedmann K. H., Sacher M., Thaler H., Vallbracht A. 1990; Clonal analysis of infiltrating T lymphocytes in liver tissue in viral hepatitis A. Immunology 69:14–19[PubMed]
    [Google Scholar]
  9. Glikson M., Galun E., Oren R., Tur-Kaspa R., Shouval D. 1992; Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore) 71:14–23[PubMed]
    [Google Scholar]
  10. Havens W. P. Jr 1944; Infectious hepatitis in the Middle East: a clinical review of 200 cases seen in a military hospital. JAMA 126:17–23 [View Article]
    [Google Scholar]
  11. Heitmann A., Laue T., Schottstedt V., Dotzauer A., Pichl L. 2005; Occurrence of hepatitis A virus genotype III in Germany requires the adaptation of commercially available diagnostic test systems. Transfusion 45:1097–1105 [View Article][PubMed]
    [Google Scholar]
  12. Karayiannis P., McGarvey M. J., Fry M. A., Thomas H. C.editors 1988 Detection of Hepatitis A Virus RNA in Tissues and Faeces of Experimentally Infected Tamarins by cDNA-RNA Hybridisation NY: Wiley-Liss;
    [Google Scholar]
  13. Locarnini S. A., Coulepis A. G., Kaldor J., Gust I. D. 1980; Coproantibodies in hepatitis A: detection by enzyme-linked immunosorbent assay and immune electron microscopy. J Clin Microbiol 11:710–716[PubMed]
    [Google Scholar]
  14. Mestecky J., Lue C., Russell M. W. 1991; Selective transport of IgA. Cellular and molecular aspects. Gastroenterol Clin North Am 20:441–471[PubMed]
    [Google Scholar]
  15. Naudet G. C. 1988 Entwicklung einer Methode zum Nachweis von IgA-Antikörpern gegen das Hepatitis A-Virus und Verlauf des Antikörpertiters im Serum. PhD thesis. Medical Faculty of the University of Tübingen, Germany (in German)
  16. Normann A., Jung C., Vallbracht A., Flehmig B. 2004; Time course of hepatitis A viremia and viral load in the blood of human hepatitis A patients. J Med Virol 72:10–16 [View Article][PubMed]
    [Google Scholar]
  17. Ping L. H., Lemon S. M. 1992; Antigenic structure of human hepatitis A virus defined by analysis of escape mutants selected against murine monoclonal antibodies. J Virol 66:2208–2216[PubMed]
    [Google Scholar]
  18. Sikuler E., Keynan A., Hanuka N., Friedman M. G., Sarov I. 1983; Detection and persistence of specific IgA antibodies in serum of patients with hepatitis A by capture radioimmunoassay. J Med Virol 11:287–294 [View Article][PubMed]
    [Google Scholar]
  19. Stapleton J. T., Lange D. K., LeDuc J. W., Binn L. N., Jansen R. W., Lemon S. M. 1991; The role of secretory immunity in hepatitis A virus infection. J Infect Dis 163:7–11 [View Article][PubMed]
    [Google Scholar]
  20. Vallbracht A., Gabriel P., Zahn J., Flehmig B. 1985; Hepatitis A virus infection and the interferon system. J Infect Dis 152:211–213 [View Article][PubMed]
    [Google Scholar]
  21. Vallbracht A., Gabriel P., Maier K., Hartmann F., Steinhardt H. J., Müller C., Wolf A., Manncke K. H., Flehmig B. 1986; Cell-mediated cytotoxicity in hepatitis A virus infection. Hepatology 6:1308–1314 [View Article][PubMed]
    [Google Scholar]
  22. Vallbracht A., Maier K., Stierhof Y. D., Wiedmann K. H., Flehmig B., Fleischer B. 1989; Liver-derived cytotoxic T cells in hepatitis A virus infection. J Infect Dis 160:209–217 [View Article][PubMed]
    [Google Scholar]
  23. Yotsuyanagi H., Koike K., Yasuda K., Moriya K., Shintani Y., Fujie H., Kurokawa K., Iino S. 1996; Prolonged fecal excretion of hepatitis A virus in adult patients with hepatitis A as determined by polymerase chain reaction. Hepatology 24:10–13 [View Article][PubMed]
    [Google Scholar]
  24. Zahn J., Vallbracht A., Flehmig B. 1984; Hepatitis A-virus in cell culture. V. Neutralizing antibodies against hepatitis A-virus. Med Microbiol Immunol (Berl) 173:9–17 [View Article][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.038406-0
Loading
/content/journal/jgv/10.1099/vir.0.038406-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error